{"id":"buphenyl","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Acidosis","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Amenorrhea/Menstrual dysfunction","drugRate":"23%","severity":"common","organSystem":""},{"effect":"Hypoalbuminemia","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Alkalosis","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Hyperchloremia","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Increased alkaline phosphatase","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Hypophosphatemia","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Decreased appetite","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Increased liver transaminases","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Leukopenia","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Leukocytosis","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Body odor","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Bad taste/Taste aversion","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Decreased total protein","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Thrombocytopenia","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Hyperuricemia","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Hyperphosphatemia","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":["Disease of liver","Kidney disease"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Aplastic anemia","drugRate":"0.5%","severity":"serious"},{"effect":"Pancreatitis","drugRate":"0.5%","severity":"serious"},{"effect":"Peptic ulcer disease","drugRate":"0.5%","severity":"serious"},{"effect":"Rectal bleeding","drugRate":"0.5%","severity":"serious"},{"effect":"Arrhythmia","drugRate":"0.5%","severity":"serious"},{"effect":"Renal tubular acidosis","drugRate":"0.5%","severity":"serious"},{"effect":"Neurotoxicity","drugRate":"0.5%","severity":"serious"},{"effect":"Syncope","drugRate":"0.5%","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Sodium Phenylbutyrate","NaPBA"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"463a36fa-3eb2-4326-8bd0-c8c7a11bca3a","title":"BUPHENYL (SODIUM PHENYLBUTYRATE) TABLET BUPHENYL (SODIUM PHENYLBUTYRATE) POWDER [HORIZON THERAPEUTICS USA, INC.]"},"ecosystem":[],"mechanism":{"target":"Aldose reductase, Histone deacetylase 1, Histone deacetylase 2"},"_scrapedAt":"2026-03-28T02:23:05.374Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Amyotrophic lateral sclerosis","diseaseId":"amyotrophic-lateral-sclerosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Citrullinemia","diseaseId":"citrullinemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Congenital hyperammonemia, type I","diseaseId":"congenital-hyperammonemia-type-i","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Deficiency of carbamylphosphate synthetase (CPS)","diseaseId":"deficiency-of-carbamylphosphate-synthetase-(cps)","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Disorder of the urea cycle metabolism","diseaseId":"disorder-of-the-urea-cycle-metabolism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ornithine Carbamyltransferase Deficiency","diseaseId":"ornithine-carbamyltransferase-deficiency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05983588","phase":"PHASE2","title":"PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Technical University of Munich","startDate":"2023-12-12","conditions":"Corticobasal Syndrome (CBS)","enrollment":32},{"nctId":"NCT06645769","phase":"EARLY_PHASE1","title":"Na-Phenylbutyrate VAscular Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-06-01","conditions":"Diabetes","enrollment":30},{"nctId":"NCT04937062","phase":"EARLY_PHASE1","title":"Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-03-01","conditions":"STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder, Developmental and Epileptic Encephalopathy","enrollment":50},{"nctId":"NCT06904027","phase":"","title":"A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-09","conditions":"Urea Cycle Disorders","enrollment":40},{"nctId":"NCT06887777","phase":"PHASE2","title":"Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-10-01","conditions":"Pyruvate Dehydrogenase Complex Deficiency Disease","enrollment":15},{"nctId":"NCT02343094","phase":"PHASE2, PHASE3","title":"Phenylbutyrate in Proteinuric Nephropathies","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Proteinuric Diseases","enrollment":26},{"nctId":"NCT06069375","phase":"PHASE2","title":"Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)","status":"SUSPENDED","sponsor":"Jerry Vockley, MD, PhD","startDate":"2024-04-01","conditions":"Medium-chain Acyl-CoA Dehydrogenase Deficiency","enrollment":24},{"nctId":"NCT04041232","phase":"EARLY_PHASE1","title":"PBA Use for Treatment of ATF6-/- Patients","status":"SUSPENDED","sponsor":"Columbia University","startDate":"2025-04-08","conditions":"ACHROMATOPSIA 7, Achromatopsia","enrollment":2},{"nctId":"NCT07125066","phase":"PHASE1","title":"An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA)","status":"ENROLLING_BY_INVITATION","sponsor":"Jerry Vockley, MD, PhD","startDate":"2025-07-30","conditions":"Combined D,L-2-hydroxyglutaric Aciduria","enrollment":1},{"nctId":"NCT03488524","phase":"PHASE2","title":"Open Label Extension Study of AMX0035 in Patients With ALS","status":"COMPLETED","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2018-03-29","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":90},{"nctId":"NCT06773026","phase":"PHASE2","title":"Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)","status":"RECRUITING","sponsor":"Jerry Vockley, MD, PhD","startDate":"2025-06-30","conditions":"Medium-chain Acyl-CoA Dehydrogenase Deficiency","enrollment":24},{"nctId":"NCT05676034","phase":"PHASE2","title":"AMX0035 in Adult Patients With Wolfram Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2023-03-03","conditions":"Wolfram Syndrome","enrollment":12},{"nctId":"NCT03533257","phase":"PHASE2","title":"Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease","status":"COMPLETED","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2018-09-14","conditions":"Alzheimer Disease","enrollment":95},{"nctId":"NCT00528268","phase":"PHASE1, PHASE2","title":"Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2007-07","conditions":"Spinal Muscular Atrophy","enrollment":22},{"nctId":"NCT05619783","phase":"PHASE3","title":"Extension Study Evaluating The Safety And Tolerability of AMX0035","status":"COMPLETED","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2022-12-29","conditions":"Amyotrophic Lateral Sclerosis","enrollment":352},{"nctId":"NCT06122662","phase":"PHASE2, PHASE3","title":"AMX0035 and Progressive Supranuclear Palsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2023-12-21","conditions":"Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases","enrollment":110},{"nctId":"NCT04421677","phase":"PHASE1","title":"Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2020-08-20","conditions":"Inclusion Body Myositis, Sporadic Inclusion Body Myositis","enrollment":10},{"nctId":"NCT01257737","phase":"PHASE4","title":"To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-10-04","conditions":"Urea Cycle Disorders","enrollment":88},{"nctId":"NCT05021536","phase":"PHASE3","title":"Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2021-10-28","conditions":"Amyotrophic Lateral Sclerosis","enrollment":664},{"nctId":"NCT01347073","phase":"PHASE3","title":"Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07","conditions":"Urea Cycle Disorders","enrollment":23},{"nctId":"NCT00947544","phase":"PHASE2","title":"Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-03","conditions":"Urea Cycle Disorders","enrollment":17},{"nctId":"NCT00551200","phase":"PHASE2","title":"Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-10","conditions":"Urea Cycle Disorders","enrollment":14},{"nctId":"NCT00999167","phase":"PHASE2","title":"A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-12","conditions":"Cirrhosis, Hepatic Encephalopathy","enrollment":189},{"nctId":"NCT00947297","phase":"PHASE3","title":"Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11","conditions":"Urea Cycle Disorders","enrollment":60},{"nctId":"NCT00992459","phase":"PHASE3","title":"Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-10","conditions":"Urea Cycle Disorders","enrollment":46},{"nctId":"NCT01948427","phase":"","title":"Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)","status":"TERMINATED","sponsor":"Amgen","startDate":"2013-09-25","conditions":"Urea Cycle Disorder","enrollment":203},{"nctId":"NCT02246218","phase":"PHASE4","title":"A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-12-31","conditions":"Urea Cycle Disorder","enrollment":27},{"nctId":"NCT03335488","phase":"PHASE4","title":"Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-02-20","conditions":"Urea Cycle Disorder","enrollment":16},{"nctId":"NCT00986895","phase":"PHASE1","title":"A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-09","conditions":"Hepatic Encephalopathy, Urea Cycle Disorders","enrollment":32},{"nctId":"NCT01135680","phase":"PHASE1","title":"Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05","conditions":"Drug Toxicity","enrollment":98},{"nctId":"NCT00977600","phase":"PHASE1","title":"A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT03127514","phase":"PHASE2","title":"AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2017-06-22","conditions":"Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases","enrollment":137},{"nctId":"NCT04987671","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS","status":"UNKNOWN","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2021-08-05","conditions":"ALS","enrollment":14},{"nctId":"NCT05836350","phase":"PHASE4","title":"Role of BCAA in Glucose Homeostasis","status":"NOT_YET_RECRUITING","sponsor":"Maastricht University","startDate":"2023-06","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT04516096","phase":"PHASE2, PHASE3","title":"A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2020-11-22","conditions":"Amyotrophic Lateral Sclerosis","enrollment":28},{"nctId":"NCT04531878","phase":"PHASE2, PHASE3","title":"BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2023-02-08","conditions":"Hereditary Diseases, Cholestasis, Intrahepatic","enrollment":""},{"nctId":"NCT05286372","phase":"","title":"An Intermediate Size Expanded Access Protocol of AMX0035 for ALS","status":"APPROVED_FOR_MARKETING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"","conditions":"Amyotrophic Lateral Sclerosis","enrollment":""},{"nctId":"NCT05349435","phase":"PHASE1","title":"A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate","status":"TERMINATED","sponsor":"Liminal BioSciences Ltd.","startDate":"2022-05-13","conditions":"Hyperammonemia","enrollment":8},{"nctId":"NCT02046434","phase":"PHASE1","title":"Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-01","conditions":"Parkinson's Disease","enrollment":38},{"nctId":"NCT02323100","phase":"PHASE1, PHASE2","title":"Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)","status":"TERMINATED","sponsor":"National Jewish Health","startDate":"2018-12-02","conditions":"Cystic Fibrosis","enrollment":13},{"nctId":"NCT03734263","phase":"PHASE2","title":"Use of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency.","status":"COMPLETED","sponsor":"Fondazione Telethon","startDate":"2018-10-01","conditions":"Pyruvate Dehydrogenase Complex Deficiency","enrollment":1},{"nctId":"NCT05028803","phase":"NA","title":"The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino Acids","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2021-09-01","conditions":"Obese Non Diabetic","enrollment":6},{"nctId":"NCT05019417","phase":"PHASE2, PHASE3","title":"Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome)","status":"UNKNOWN","sponsor":"Kaplan Medical Center","startDate":"2021-06-30","conditions":"Monocarboxylate Transporter 8 Deficiency","enrollment":6},{"nctId":"NCT00387530","phase":"PHASE2","title":"Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2006-05","conditions":"Gastric Cancer, Head and Neck Cancer, Lymphoma","enrollment":""},{"nctId":"NCT01529060","phase":"PHASE2, PHASE3","title":"Phenylbutyrate Therapy for Maple Syrup Urine Disease","status":"COMPLETED","sponsor":"Brendan Lee","startDate":"2013-02","conditions":"Maple Syrup Urine Disease","enrollment":20},{"nctId":"NCT02094222","phase":"","title":"Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Robert Squires, Jr.","startDate":"","conditions":"Byler Disease","enrollment":""},{"nctId":"NCT00005639","phase":"PHASE1","title":"Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2000-03","conditions":"Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":34},{"nctId":"NCT00771901","phase":"NA","title":"Effect of Endoplasmic Reticulum Stress on Metabolic Function","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2008-02","conditions":"Insulin Resistance, Diabetes, Obesity","enrollment":101},{"nctId":"NCT00345605","phase":"PHASE2","title":"Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder","status":"COMPLETED","sponsor":"Brendan Lee","startDate":"2008-02","conditions":"Argininosuccinic Aciduria, Amino Acid Metabolism, Inborn Errors, Urea Cycle Disorders","enrollment":12},{"nctId":"NCT02111200","phase":"NA","title":"Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-09","conditions":"Urea Cycle Disorders, Inborn","enrollment":7},{"nctId":"NCT00006239","phase":"PHASE1","title":"Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2000-12","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases","enrollment":""},{"nctId":"NCT01881984","phase":"PHASE1","title":"Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-06","conditions":"Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency","enrollment":4},{"nctId":"NCT01698476","phase":"PHASE2","title":"Immune Reconstitution in Tuberculosis Disease","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2012-09","conditions":"Pulmonary Tuberculosis (TB)","enrollment":390},{"nctId":"NCT01702974","phase":"PHASE2","title":"Immune Reconstitution in HIV Disease (IREHIV)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2012-09","conditions":"HIV Infection","enrollment":279},{"nctId":"NCT00006240","phase":"PHASE2","title":"Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2000-10","conditions":"Leukemia","enrollment":""},{"nctId":"NCT01580007","phase":"PHASE2","title":"Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2010-12","conditions":"Pulmonary Tuberculosis","enrollment":288},{"nctId":"NCT01949766","phase":"","title":"Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease","status":"NO_LONGER_AVAILABLE","sponsor":"University of Pittsburgh","startDate":"","conditions":"Byler Disease","enrollment":""},{"nctId":"NCT00006019","phase":"PHASE2","title":"Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-05","conditions":"Leukemia, Lung Cancer, Lymphoma","enrollment":""},{"nctId":"NCT01784718","phase":"","title":"Buphenyl Therapy for Byler's Disease","status":"NO_LONGER_AVAILABLE","sponsor":"University of Pittsburgh","startDate":"","conditions":"Byler Disease","enrollment":""},{"nctId":"NCT00002909","phase":"PHASE1","title":"Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1997-02","conditions":"Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":24},{"nctId":"NCT00002796","phase":"PHASE1, PHASE2","title":"Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"1997-05","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":46},{"nctId":"NCT00762112","phase":"PHASE3","title":"Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2003-11","conditions":"Diabetes Mellitus","enrollment":316},{"nctId":"NCT00762684","phase":"PHASE3","title":"Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2004-11","conditions":"Diabetes Mellitus","enrollment":8},{"nctId":"NCT00763022","phase":"PHASE3","title":"Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-11","conditions":"Diabetes Mellitus","enrollment":302},{"nctId":"NCT00762190","phase":"PHASE3","title":"Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2003-11","conditions":"Diabetes Mellitus","enrollment":348},{"nctId":"NCT01096095","phase":"PHASE2","title":"Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3","status":"WITHDRAWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2010-06","conditions":"Spinocerebellar Ataxia Type 3","enrollment":""},{"nctId":"NCT00212316","phase":"PHASE2","title":"Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2005-08","conditions":"Huntington's Disease","enrollment":60},{"nctId":"NCT00762957","phase":"PHASE3","title":"Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.","status":"TERMINATED","sponsor":"Takeda","startDate":"2004-11","conditions":"Diabetes Mellitus","enrollment":15},{"nctId":"NCT00759720","phase":"PHASE3","title":"Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.","status":"TERMINATED","sponsor":"Takeda","startDate":"2003-11","conditions":"Diabetes Mellitus","enrollment":447},{"nctId":"NCT00590538","phase":"PHASE1, PHASE2","title":"Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)","status":"TERMINATED","sponsor":"Children's Hospital of Philadelphia","startDate":"2003-02","conditions":"Cystic Fibrosis","enrollment":9},{"nctId":"NCT00439218","phase":"PHASE1, PHASE2","title":"Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I","status":"TERMINATED","sponsor":"Westat","startDate":"2008-01","conditions":"Spinal Muscular Atrophy Type I","enrollment":5},{"nctId":"NCT00439569","phase":"PHASE1, PHASE2","title":"Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III","status":"TERMINATED","sponsor":"Westat","startDate":"2008-01","conditions":"Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III","enrollment":9},{"nctId":"NCT00533559","phase":"PHASE4","title":"Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2007-09","conditions":"Diabetes, Insulin Resistance","enrollment":10},{"nctId":"NCT00004871","phase":"PHASE1","title":"Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2000-05","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases","enrollment":""},{"nctId":"NCT00107770","phase":"PHASE1, PHASE2","title":"Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-04","conditions":"Amyotrophic Lateral Sclerosis","enrollment":40},{"nctId":"NCT00016744","phase":"PHASE1, PHASE2","title":"Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2001-09","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT00001565","phase":"PHASE1","title":"Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-12","conditions":"Brain Neoplasms, Neuroblastoma","enrollment":35},{"nctId":"NCT00005934","phase":"PHASE2","title":"5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2000-06","conditions":"Beta Thalassemia","enrollment":24},{"nctId":"NCT00006450","phase":"PHASE2","title":"Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-11","conditions":"Brain Tumor","enrollment":120},{"nctId":"NCT00004767","phase":"PHASE2","title":"Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1985-01","conditions":"Amino Acid Metabolism, Inborn Errors","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":39,"reaction":"HYPERAMMONAEMIA"},{"count":29,"reaction":"VOMITING"},{"count":27,"reaction":"OFF LABEL USE"},{"count":19,"reaction":"AMMONIA INCREASED"},{"count":12,"reaction":"HYPERAMMONAEMIC CRISIS"},{"count":11,"reaction":"DEATH"},{"count":9,"reaction":"CONDITION AGGRAVATED"},{"count":9,"reaction":"DECREASED APPETITE"},{"count":9,"reaction":"DIARRHOEA"},{"count":8,"reaction":"HEADACHE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Buphenyl","genericName":"Buphenyl","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}